In the News

Aragen Life Sciences: Trusted R&D and Manufacturing Partner

Aragen shares 2026 predictions

Incidence of Spontaneous and Urethane-Induced Tumors in a 26-Week Carcinogenicity Study in Tg.rasH2 Mice Sourced From CLEA, Japan

Mechanistic insights into PROTAC-mediated degradation through an integrated framework of molecular dynamics, free energy landscapes, and quantum mechanics: A case study on kinase degraders

Globalising ADC development in the US and beyond

Aragen strengthens Discovery leadership with the appointment of Neeraj Garg as CEO

Aspire to Inspire

Accelerating Vaccine Development with Cutting-edge R&D to Support Global Health Initiatives

Advanced Strategies for Balancing Yield, Stability, and Quality in ADC Production

The Evolving Science Behind Formulation Development

Aragen Life Sciences eyes IPO as it expands global footprint with biologics, ADCs

India’s CDMOs, CRDMOs to benefit from global biopharma’s increased outsourcing: report

US tariffs could undo generic drugmakers' efforts to be less reliant on Chinese raw materials, experts say

Avendus, SBI Life pick up over 2.5% secondaries in Aragen for Rs 300 crore

Aragen talks manufacturing in Bangalore as qualification nears

Aragen appoints Aniel Khubchandani as CEO of Development and Manufacturing Solutions business

Customizable Relationships Enhance Speed to Market

Q&A: Aragen receives EcoVadis platinum certification

Advancing the development of deep learning and machine learning models for oral drugs through diverse descriptor classes: a focus on pharmacokinetic parameters (Vdss and PPB)

Aragen’s biologics manufacturing facility completes qualification; first GMP batches in late July 2025

Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient and Secure

IPSO expects the govt to help set up infrastructure dedicated to the Indian CRDMO industry

Why Chemistry Still Matters: The Heart of Successful CRDMO Execution

Aragen, the first indian company to be rated platinum by ecovadis

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

CDMOs anticipate inspection bottlenecks after mass FDA firings

Pharma tariffs: Here’s what a potential rollout could look like

Industry Leaders Drive CRDMO Reform, Unite Under IPSO for a Transformational Leap

India’s Aragen sees rising demand for CRDMO services amid changes in geopolitical landscape

Aragen appoints Dr. Manjunath Ramarao as Chief Scientific Officer and Executive Vice President, Integrated Drug Discovery; Jayadeva Sajankila as Vice President and Head, Chemical Development Solutions

Targeted protein degraders: Blood–brain barrier permeability and central nervous system exposure

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035, driving global pharma innovation: BCG-IPSO Report

2025 – The year ahead

Aragen $100m PE boost to bolster CDMO ambition in India and beyond

Aragen secures $100 Mn investment from Quadria Capital

Merck KGaA, Aragen Execs On AI-Led Drug Discovery, Incubator Set-up, US Tariffs And More

Automation accelerators in drug discovery and development

IRA matches BIOSECURE in driving CDMO sector in India

Unpacking Global Biopharma Business Relations with Ashu Tandon

Biotech Industry's Path Towards Sustainability

Navigating the future: building a de-risked supply chain

Indian CDMOs form trade group

Algorithms to Treatments: AI’s Impact on Modern Drug Discovery

Biologics Roundtable: The Current Landscape and Future Developments

Indian drug services companies unite

Clients add pressure to CDMOs to source raw materials outside of China, execs say

Developing capabilities to profile the next gen compounds in new modalities is expected to drive preclinical CRO growth

CDMO strategies for disrupting the biomanufacturing scale-up paradigm

DevsHealth announces strategic partnership with Aragen for the chemical synthesis of its projects

Enhancing Supply Chain Flexibility and Resilience

Aragen Life Sciences receives Science Based Targets initiative (SBTi) approval for its greenhouse gas emission reduction targets

India seeks a seat at the drug services table

Expert View: Understanding the India CDMO Market

CDMO trends post-Wuxi’s exit from the US: who will take its place?

Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership Award from Frost & Sullivan for Pioneering Excellence in Drug Discovery and Development Services

The Discovery and Patent Acquisition of a New Hair Growth Substance

CII Telangana CEO’s Round Table on Policy and Advocacy Discussion on Pharma Service

Biosecurity threats and business as usual

Home and US CAPEX places India on brink of bioCDMO breakthrough

Three Indian CDMOs ready to seize the BIOSECURE Act opportunity

Aragen Bioscience Validates Getinge's Single-Use Production Reactor (SUPR)

Subodh Deshmukh and Ramesh Subramanian

Aragen’s Formulation Manufacturing Facility Achieves GMP Certification from Telangana Drugs Control Administration

Aragen's Validation Journey with Getinge's SUPR Single-Use Bioreactors

Contract Manufacturing: Pharma’s New Growth Pill

Indian CDMOs expand capacities: Syngene and Aragen lead the way

Biopharma manufacturing ‘turbulence’ boosts inquiries for India-based providers, local CDMO execs say

Aragen operationalizes first phase of its Biologics manufacturing facility in India

DHL Express India and Aragen LifeSciences sign GoGreen Plus partnership to reduce carbon emissions

Aragen Life Sciences expands its operations from Hyderabad

Ramesh Subramanian shares insights with LSKH – Life Sciences Knowledge Hub

Innovations in Pharmaceutical R&D: Navigating the Future.

Indian drug manufacturers benefit from Big Pharma interest beyond China

Beyond Manufacturing: Broadening Horizons of CDMOs

"We expect biologics manufacturing to be a major area of contract services growth in the next 2-3 years."- Ramesh Subramanian on Aragen's upcoming biologics manufacturing facility

Targeted Protein Degraders- The druggability perspective

Heard at #CPHI: VC funding trends; Samsung eyes expansion; and supply chain diversification

Aragen setting up a $ 30 million bio-manufacturing site in India

Aragen Commissions a state-of-the-art Formulations Manufacturing Facility in Hyderabad, India

Driving Dosage Form Developments

We propose an export zone for project approvals from the government, enabling rapid manufacture of chemicals and products for global companies

Forging robust partnerships in biologics development

FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegeneration

Long-acting injectables for biologics: Current landscape and future perspective

Aragen expands collaboration with Blueprint Medicines

Chief Executive Officer (MK) & Chief Commercial Officer (RS), Aragen Life Sciences

Aragen continues to ride CDMO growth wave as CEO honoured at CPHI Awards

Best practices & strategies for biotherapeutics production using a stable scale-up process

CSIR-IICT, Aragen and Kewaunee sign MOU for offering “Finishing School” skill program to postgraduate students in Chemistry

CPHI Pharma Award Winners 2022: CEO of the Year – Aragen Life Sciences

Predicting Pharma’s Future

China’s challenge in the drug services field

Automation accelerators in drug discovery and development

Cell line platform reduces timelines by 33%, says Aragen

Aragen sets it sights on biologics manufacturing with India facility

Aragen launches royalty-free CHO GS cell line development platform under RapTr2022

Aragen to operationalize cutting-edge formulation manufacturing facility in Hyderabad, India

Aragen extends collaboration with NeoVac

Aragen Life Sciences: Strengthening A Positive Work Culture Through Employee Empowerment

V Madhusudan, CEO - Projects, TSIIC Limited and Manni Kantipudi, CEO, Aragen Life Sciences lay foundation stone for minor bridge and VRCC Stormwater drain at Mallapur

Aragen expands collaboration with MSD to provide discovery services to support MSD’s global R&D

Targeted Protein Degradation: Challenges And Opportunities

Challenges In Developing Effective Therapeutics Against Respiratory Syncytial Virus Infection

Analytical Prowess Powers Efficient CLD Through Data-Driven Decision-Making

Manni Kantipudi (Chief Executive Officer) & Ramesh Subramanian (Chief Commercial Officer), Aragen Life Sciences, in an exclusive interview with GBR

India’s One-Stop Shops

Electron mobility with photoredox catalysis

Responsible Growth

Employer Branding: Imperative for talent attraction and retention

Aragen Life Sciences donates ambulance to Government of Telangana

Aragen receives Great Place to Work certification for the 3rd consecutive year

Balancing Internal Focus Against External Capabilities

Integrated CDMO Growth Will Lead to Patients Seeing Record Number of Drugs Making it to Market

Testing Cell Line Development Technology Platforms In Parallel

Why this company focuses on employee branding to retain top notch talent

CDMO industry to see increasing consolidation both in global and Indian markets: Manni Kantipudi

Developments and Discovery in Modern Drug Research

Aragen acquires Intox Pvt. Ltd.

"Business Growth Is Directly Proportional To Employee Satisfaction"

Aragen focuses on securing biologics capacity within ‘competitive’ CDMO space

Aragen expects to ride wave of US biotech growth in 2022

Career in Life Sciences - Outlook and opportunities

Clearmind Signs Development and Supply Agreement to Produce its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences

Branding CROs/CDMOs: Aragen, a case in point

Post pandemic future for CROs and CDMOs in India

Goldman Sachs-backed Aragen Life Sciences on expansion mode, evaluating select acquisition opportunities

“R&D outsourcing has become a ‘must have’ than ‘good-to have’ strategy”

Hyderabad-based Aragen accelerating drug, vaccine development

Hyderabad-based Aragen to expand footprint in US

Aragen: A Collaborative Initiative To Improve Human Lives

Big ambitions for India’s contract research firms

GBR: Interview with Manni Kantipudi, CEO and Ramesh Subramanian, CCO Aragen Life Sciences

Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"

Ramesh Subramanian, Chief Commercial Officer at Aragen speaks about “CDMO deal-making in a pandemic and beyond” at CPhI North America

Manni Kantipudi, CEO, Aragen Life Sciences speaks in-depth about the company’s brand story and value differentiators in this interview with Pharma Focus Asia

Aragen Announces Partnership with Skyhawk Therapeutics, Aimed at Developing Novel Small Molecule Therapeutics that Correct RNA Expression.

Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim

Covid – 19 vaccination drive for employees in Mallapur Industrial Area Local Authority (IALA) community

Aragen announce multi-year partnership with FMC Corporation, aims at accelerating Agro-chemical pipeline

GBR: Interview with Manni Kantipudi, CEO and Ramesh Subramanian, CCO Aragen Life Sciences

Aragen (Formerly GVK BIO) To Partner With Global Biopharma With a Renewed Brand Promise

ETHealthworld: Interview with Ramesh Subramanian,
Chief Commercial Officer, Aragen

Goldman Sachs Invests in Aragen Life Sciences

On Demand Webinar:Targeted Protein Degradation in Inflammation and Cancer Therapy

Pharma Bio: Interview with Dr Somesh Sharma

Celerity™ Supply Chain Tribe: Interview with Chandan Shirbhayye

Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19

Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate the Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Candidate

Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process

Aragen Bioscience and University of Technology, Sydney Enter MoU to Support and Accelerate Biologics R&D in Australia

Aragen Bioscience Announces the Appointment of Steven Lang, PhD, MBA as Vice President, Biologics

Serum Institute and Aragen Bioscience Announce Collaboration on Vaccine Development

GVK BIO Announces the Promotion of Sudhir Kumar Singh to Chief Operating Officer and the Appointment of Ramesh Subramanian as its New Chief Commercial Officer

Drug Discovery: In Drug Discovery, it’s About Time

Biological E and GVK BIO Announce Strategic R&D Partnership

GVK BIO Announces the Appointment of Robert R. Ruffolo, PhD, to its Board of Directors

GVK BIO Announces USFDA Approval for its cGMP Analytical Services Laboratory

Telangana Today: GVK BIO Eyes Expansion - Targets Europe, US and China; Completes Inspection at its lab in Mallapur in Hyderabad

LifeArc and GVK BIO Celebrate a Decade Of Partnership, Transforming Research Into Life-Saving Medicines

GVK BIO Announces the Appointment of Axel Schleyer, PhD as Chief Executive Officer, Aragen Bioscience, Inc.

GVK BIO Certified as an Authorized Economic Operator by CBIC

GVK BIO Receives Second Runner Up Award at YES Bank’s Natural Capital Awards 2018

Aragen Bioscience Expands RapTr Cell Line Development Services

GVK BIO declared the 1st Runner-Up under the Innovation and Technology Category

Aragen Bioscience Announces AAALAC Accreditation

GVK Biosciences Completes 10 years in Collaboration with Nuevolution

Telangana Today: GVK BIO Ramping up Operations

GVK Biosciences Launches eCule, India’s First Mobile App for Drug Discovery solutions

CFI.co: GVK Biosciences: Pushing the Envelope

GVK BIO Launches Mobile App

Business Trends: Delivering Research for Global Life Science Industry

CFI.co Meets the CEO of GVK Biosciences: Manni Kantipudi

Global Business Reports: GVK Recently Constructed Mumbai’s Much Acclaimed New Airport

GVK Biosciences Receives Best Life Sciences QHSE Leadership India 2017

GVK Biosciences Inaugurates a Process Engineering & Safety Evaluation Lab

Project Ascent Goes Live

RapTr Cell Line Development Services Introduced

GVK BIO Stamps its Presence at the BIO International Convention

GVK Biosciences Announces the Launch of a GMP-compliant Analytical Services Laboratory

Aragen Bioscience Announces Licensing Agreement for Protein Production Technology from ProteoNic Biotechnology

GVK Biosciences Renews AAALAC International Accreditation in Animal Care

GVK Biosciences Awarded Confederation of Indian Industry EHS Excellence Award 2016

Aragen Bioscience Announces the Appointment of President

GVK BIO wins the Global CSR Excellence & Leadership Awards

Dow AgroSciences wins the Agrow Awards for Best Industry Collaboration with GVK Biosciences

Increased Focus within Medivir’s R&D and Optimizing Resources Through a Partnership with GVK BIO

Akaal Pharma, Australia Extends Collaboration with GVK BIO for Formulations Development Services to Support Phase II Clinical studies for the Topical Treatment of Psoriasis

GVK Biosciences Strengthens its Tie-up with CTC Life Science Corporation, Japan

GVK Biosciences Donates Rs. 20 Lakh to the Andhra Pradesh Chief Minister’s Relief Fund, Towards Cyclone Hudhud Relief Efforts

GVK Biosciences Announces the Successful Completion of Drug Repurposing Efforts to Identify Novel Indications

NanoHealth (ISB Alumni Venture) Partners with GVK Biosciences for the use of GVK BIO’s Proprietary HEART platform

GVK Biosciences and Aragen Bioscience Sign Definitive Agreement to Acquire Aragen Bioscience, Inc.

GVK Biosciences and USFDA Announce Drug Repositioning Collaboration – License to GVK BIO SAR Database GOSTAR

Drug Discovery Unit (DDU), University of Dundee Licenses GVK Biosciences’ Online SAR Database, GOSTAR

GVK Biosciences Announces New Distributor in Taiwan

USFDA Extends the License of the GVK BIO Biomarker Database

GVK Biosciences Enters Into Research Collaboration with Endo Pharmaceuticals

GVK Biosciences and Onconova Therapeutics Establish a Novel Joint Development Partnership to Advance New Drugs for Cancer

GVK BIO Establishes the Largest Isotope Labeling Facility in India

GVK Biosciences Licenses its Biomarker Database to The Division of Cancer Prevention, National Cancer Institute

BioAsia 2012 from February 09; GVK Biosciences is Co-Industry Host

GVK BIO Announces Multi-year Drug Discovery Collaboration

GVK Biosciences Presented the Frost & Sullivan Growth Leadership Award in the Contract Research Service Market

GVK Biosciences Partners with the PROOF Centre of Excellence, University of British Columbia in Biomarker Development and Commercialization

GVK Biosciences Extends the License of its SAR Databases to Astellas Pharma

Indiana CTSI Partners with GVK Biosciences to Provide National Access to Biomarker Database

GVK Biosciences is the Preferred Provider to Global Health Product Development Partners Consortium to Focus on Drugs and Vaccines for Neglected Infectious Diseases

GVK Biosciences Extends License of its Biomarker Database to the USFDA

Asian Biotech Award for GVK Biosciences Chief

Dow AgroSciences Identifies Lead Molecule in Collaboration with GVK Biosciences

GVK Biosciences Receives AAALAC Accreditation for its Animal Facility

GVK Biosciences Appoints Dr John Ellingboe as Senior Vice President, Discovery Chemistry

Asia Life Science Services Resource Guide 2010: Contract Research in India – Cost, Developmental and Regulatory Issues

Bayer Crop Science Signs Agreement with GVK Biosciences on Early-Stage Research Projects

GVK Biosciences is the Winner of the European Outsourcing Award 2009 for Best New Partnership along with Wyeth Research

GVK Biosciences and Quantitative Solutions Collaborate on Clinical Trial Outcome Databases

GVK Biosciences Announces Appointment of Gerhard N Mayr to its Board of Directors

GVK Biosciences Organizes Workshop on Clinical Trials

GVK Biosciences Announces Agreement With University of Tokyo on GPCR Database

GVK Biosciences Responds to DCGI’s Letter on Clinical Trial of Wyeth’s Investigational Vaccine

GVK Biosciences and Crelux set up Fragment-Based Drug Discovery Platform to Deliver Lead Molecules